Novartis rolls out its next big drug at a record-setting price of $2.12M — let the gene therapy pricing debate begin
Let the next big debate over gene therapy pricing begin now.
Novartis announced midday Friday that the FDA had stamped its OK on Zolgensma, a groundbreaking gene therapy for lethal cases of spinal muscular atrophy that will test the market’s acceptance of 7-figure prices.
After years of discussion and debate, Novartis set the price at $2.12 million spread out over a 5-year installment plan.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,600+ biopharma pros reading Endpoints daily — and it's free.